Search

Your search keyword '"Houben S"' showing total 79 results
Start Over Author "Houben S"
79 results on '"Houben S"'

1. Hybrid Hydrogels with Orthogonal Transient Cross-linking Exhibiting Highly Tunable Mechanical Properties

Author

Houben, S., Aldana, A.A., Huysecom, A.S., Mpinganzima, W., Cardinaels, R., Baker, M.B., Pitet, L.M., Houben, S., Aldana, A.A., Huysecom, A.S., Mpinganzima, W., Cardinaels, R., Baker, M.B., and Pitet, L.M.

Abstract

Compositional changes in the chemical makeup of hydrogels offer a powerful strategy for fine tuning of mechanical properties, enabling specific targeting for different applications. The chemical versatility exhibited by the tunable system introduced here can be leveraged to address a broad range of characteristics across the field of tissue engineering-from blood vessels to cartilage, for example-which demands materials with very different mechanical profiles. Furthermore, we rely exclusively on dynamic, non-covalent cross-linking to provide opportunities for 3D printing and injectability. This work describes a highly tunable system based on hydrogen bonding and ionic interactions. Single network hydrogels were made by exploiting various acrylic monomers including N-acryloyl glycinamide (NAGA) and acrylic acid (AAc). Additionally, hybrid hydrogels were explored by combining these acrylic networks with an ionically cross-linked alginate network. By combining orthogonal cross-linking strategies and altering the ratio between different components in these hybrid gels, a broad range of mechanical properties is demonstrated. The characteristics were extensively investigated using tensile testing, compression testing, and rheological measurements. The final scaffolds were also shown to be non-cytotoxic in preliminary cell viability studies for human dermal fibroblasts.

Published
2023

5. An Accelerated Poincaré-Map Method for Finding the PSS of Autonomous Oscillators

Author

Houben, S. H. M. J., Maubach, J. M., Bock, Hans-Georg, editor, Dehoog, Frank, editor, Friedman, Avner, editor, Langford, William, editor, Neunzert, Helmut, editor, Pulleyblank, William R., editor, Rusten, Torgeir, editor, Tornberg, Anna-Karin, editor, Capasso, Vincenzo, editor, Mattheij, Robert, editor, Anile, Angelo Marcello, editor, and Greco, Antonio, editor

Published
2002
Full Text
View/download PDF

10. Oppervlakkige afspoeling van gewasbeschermingsmiddelen naar oppervlaktewater : Handelingsopties en Good Practices : Deltafact

Author

Wenneker, M., Houben, S., Kruijne, R., Wenneker, M., Houben, S., and Kruijne, R.

Abstract

In dit Deltafact zijn de kennis en inzichten en adviezen over afspoeling van gewasbeschermingsmiddelen bijeengebracht in praktijkgerichte opties om de kennis beter te benutten en om bruikbare kennis inzichtelijk te maken. De good practices in dit deltafact zijn ook opgenomen in de tool “Inzicht in Maatregelen tegen Afspoeling van middelen vanaf Percelen (IMAP)”. Met IMAP krijgt de teler inzicht in de situatie per perceel en de mogelijke toepasbare maatregelen.

Published
2022

13. Trends in Double Networks as Bioprintable and Injectable Hydrogel Scaffolds for Tissue Regeneration

Author

Aldana, A.A., Aldana, A.A., Houben, S., Moroni, L., Baker, M.B., Pitet, L.M., Aldana, A.A., Aldana, A.A., Houben, S., Moroni, L., Baker, M.B., and Pitet, L.M.

Abstract

Additive manufacturing and injection are essential tools in the rapidly developing field of personalized medicine and are particularly promising for applications in regenerative medicine. One of the biggest challenges in this vibrant research domain remains the processing of complex formulations with robust mechanical properties. Mimicking the native extracellular matrix associated with many tissues requires materials that have high degrees of functionality for performing the complex array of functions within the cellular environment. Furthermore, native tissues often possess outstanding mechanical properties, particularly in connective tissues. These exceptional mechanics are a challenge to emulate in their own right, especially considering the accompanying demands for additional functionality. Double-network hydrogels have emerged as strong candidates for tissue engineering because of the impressive mechanics and versatility in terms of chemical makeup. Combining advances in processing (i.e., additive manufacturing and injection) with dual-network hydrogel formulations has led to an impressive collection of results, making great strides toward systems capable of addressing the demanding environment surrounding tissues while being amenable to personalized fabrication techniques. This review provides a brief summary of the most contemporary trends collected from the literature describing dual-network hydrogels being demonstrated in additive manufacturing and injectable applications.

Published
2021

20. Effecten van vochthuishouding en bodemtemperatuur op de aardappelplant : Zetmeelaardappelteelt onder droge en warme condities

Author

Dogterom, J., Houben, S., Wander, J., Dogterom, J., Houben, S., and Wander, J.

Abstract

Water is cruciaal voor een goede teelt, zeker in een teelt als zetmeelaardappel waarbij de planten in ruggen groeien, een relatief ondiepe bewortelingsdiepte (40-60 cm) hebben en de vochthuishouding en temperatuur bepalend zijn voor de inhoudsstoffen (suiker- en zetmeelgehalte) van de knollen. Met de klimaatverandering ontstaan hogere temperaturen, langere perioden van droogte en korte perioden van veel neerslag, waardoor goed beheer van het microklimaat belangrijker wordt. Irrigatie voor koeling en vochtvoorziening wordt daarmee belangrijker. Om de zetmeelaardappelteelt onder warmere en drogere groeiomstandigheden op voldoende niveau te houden, wordt in deze literatuurstudie onderzocht wat de effecten van irrigatie, temperatuur, zonnestraling en gerelateerde maatregelen zijn op de aardappelplant. Op basis van deze gegevens en ervaringen uit gebieden waar aardappelen reeds onder warme en/of droge omstandigheden worden geteeld, wordt richting gegeven voor aanpassingen van de Nederlandse zetmeelaardappelteelt.

Published
2019

22. Surface micropatterning of uniaxially oriented polyethylene films using interference holography for strain sensors

Author

Shen, L., Lafleur, S.D., Houben, S J.A., Murphy, J.N., Severn, J.R., Bastiaansen, C.W.M., Shen, L., Lafleur, S.D., Houben, S J.A., Murphy, J.N., Severn, J.R., and Bastiaansen, C.W.M.

Abstract

A new procedure is presented for direct generation of surface micropatterns on uniaxially oriented polyethylene (PE) films using interference holography with a nanosecond pulsed laser. An ultraviolet absorber, 2-(2H-benzotriazol-2-yl)-4,6-di-tert-pentylphenol (BZT) is incorporated into PE prior to stretching to generate absorption at the wavelength of the laser. Illumination with an interference pattern in the absorption band of BZT leads to an obvious height variation in the exposed regions and consequently relief gratings are generated. The height in the exposed regions is strongly dependent on the angle between the grating direction and the film orientation direction. This phenomenon is attributed to a combination of events such as melting, entropic contraction, recrystallization, thermal evaporation of BZT, and anisotropic thermal conductivity. It is shown that the relief height increases with increasing BZT concentration and exhibits a linear dependence on the energy dose above a certain threshold. Additionally, the oriented PE films with the surface micropatterns are explored for strain sensors. The results demonstrate that small strains below 10% are monitored accurately in tensile deformation of the micropatterned, oriented PE films which makes these films potentially useful as strain sensors.

Published
2017

24. Bibliografie Limburgse Naamkunde

Author

Belemans, R., Slechten, P., Houben, S., Janssen, D., Meijers, M., Mennen, V., Segers, J., and Wijngaard, H.H.A. van de

Subjects
Letteren en Geschiedenis, Linguistics, Sociolinguistiek, Taal in sociale context, Menswetenschappen, Taal en Cultuur, Toegepaste taalwetenschap
Abstract

Item does not contain fulltext

Published
1997

26. Toepassing van de ELISA-test in de varkensteelt

Author

Houben, S., Tensaert, M.B., Houben, S., and Tensaert, M.B.

Abstract

Resultaten van urologische studies naar het PRRSV (abortus blauw) antistoffenverloop bij biggen en zeugen

Published
1995

30. Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.

Author

Peters, Frank P. J., Lalisang, Roy I., Fickers, Martin M. F., Erdkamp, Frans L. G., Wils, Jacq A. J. M., Houben, Sjef G. J., Wals, Jaap, Schouten, Harrie C., Peters, F P, Lalisang, R I, Fickers, M M, Erdkamp, F L, Wils, J A, Houben, S G, Wals, J, and Schouten, H C

Subjects
THERAPEUTICS, PHARMACOLOGY, DRUG therapy, DRUGS, MEDICAL supplies, ANTINEOPLASTIC agents, DOXORUBICIN, LYMPHOMAS, PREDNISONE, SURVIVAL analysis (Biometry), VINCRISTINE, RETROSPECTIVE studies, CYCLOPHOSPHAMIDE, MITOXANTRONE, PREDNISOLONE
Abstract

Purpose and Methods: Nowadays more people are becoming older. The median age of a patient with non-Hodgkin's lymphoma (NHL) at diagnosis is over 60 years. The incidence of NHL in elderly has increased in the last decades. Therefore, in the future, NHL will be diagnosed more often in the elderly. Data of all patients in the south-east of the Netherlands with newly diagnosed NHL between January 1991 and January 1995 were analysed in a retrospective multicentre population-based study to investigate if and how elderly patients (> 60 years) with advanced NHL (Ann Arbor Staging > or = IIB) of intermediate- and high-grade malignancy were treated. Treatment modalities applied, outcome, and causes of death were evaluated. Treatment was considered inadequate if it deviated from the standard anthracycline-containing chemotherapy (CNOP/CHOP) for a minimum of six cycles.Results: The entry criteria were met by 68 patients. Of these patients, 57 (83.8%) were treated and 11 (16.2%) were not treated. The treatment consisted of CHOP (36 patients), CNOP (6 patients), chlorambucil (13 patients), or COP (2 patients). Forty-two of 68 patients had adequate treatment, but 14 of 42 (33.3%) patients had a suboptimal numbers of cycles (< 6). Of 28 patients with adequate chemotherapy, only 16 had the optimal number of cycles and dose; the result is that the treatment of 76.5% (52/68) of patients differed from that of their younger counterparts. The most important reason for treatment not being optimal was high age (23%) or poor performance (35%). In the appropriately treated patients, 62.5% (10/16) had a complete response. Survival in the CHOP/CNOP-treated group was better than in other groups. The main cause of death in the total study group was NHL. The results cannot be explained by the different international prognostic index.Conclusion: A significant subset (76.5%) of elderly people with intermediate/high-grade NHL received suboptimal therapy, mainly because of a suboptimal performance status. However, a significant part of the patients (23%) were not treated optimally because of high age, despite a good performance. For improving the overall survival in the elderly, it is not only the schedule that is important, but also the intention to treat the elderly patient. [ABSTRACT FROM AUTHOR]

Published
2001
Full Text
View/download PDF

31. Combination of Tevatron searches for the standard model Higgs boson in the W+W- decay mode

Author

Maxim Perfilov, B. Carls, V. Sorin, P. Lukens, Kevin Lannon, P. Verdier, Guenakh Mitselmakher, Guillelmo Gomez-Ceballos, Marcelo Vogel, V. A. Kuzmin, U. K. Yang, Chris Hays, W. T. Fedorko, Y. A. Yatsunenko, M. Mussini, Y. C. Yang, J. Keung, G. C. Blazey, D. Torretta, A. F. Barfuss, L. Bellantoni, Viatcheslav Stolin, Frank Würthwein, M. Shochet, C. Plager, F. Canelli, V. A. Bezzubov, A. Hocker, P. D. Grannis, Jun Guo, Q. Z. Li, Mark Kruse, Alison Lister, J. P. Fernandez, J. P. Negret, J. Nett, Stefano Giagu, Paul Tipton, G. L. Strycker, C. Mesropian, R. Yamada, D. N. Brown, P. Squillacioti, Kazuhiko Hara, J. Osta, Carlos Avila, L. E. Kirsch, Ricardo Eusebi, J. Galyardt, Alexei Safonov, R. Luna-Garcia, Raimund Ströhmer, V. Simak, D. Krop, Sabine Lammers, Jonas Rademacker, D. Amidei, J. M. Heuser, J. Sekaric, Michael A. Strauss, Jean-Francois Grivaz, K. Devaughan, A. T. Goshaw, P. Padley, Michael Hildreth, P. Skubic, A. Semenov, D. Clark, J. Boudreau, Wendy Taylor, M. Pangilinan, Jason Nielsen, G. Introzzi, B. Casal, Mitchell Wayne, N. Miladinovic, Y. Tu, H. Schellman, J. M. Kohli, K. Potamianos, Z. Gunay-Unalan, Darren Price, A. Sanchez-Hernandez, M. Wiok, Sergo Jindariani, Fedor Prokoshin, P. Jonsson, Thomas Hebbeker, Katsufumi Sato, A. J. Slaughter, Stefan Grünendahl, S. Cihangir, V. Zutshi, Yasuyoshi Nagai, Francesco Crescioli, S. Uzunyan, S. W. Lee, P. Ttito-Guzmán, T. Okusawa, B. Gómez, R. Madrak, Chong-Yu Xu, J. Naganoma, B. Tuchming, P. Wagner, V. Bunichev, Shinhong Kim, J. Budagov, Fabrice Couderc, K. Makhoul, Manfred Paulini, B. Tiller, Dmitri Tsybychev, R. L. McCarthy, Thomas LeCompte, Manuela Campanelli, I. Lazzizzera, Eva Halkiadakis, M. Gold, Tetsuo Arisawa, C. Neu, Amnon Harel, W. M. Lee, K. Kondo, Mary Beth Adams, D. Whiteson, I. Shreyber, K. Yamamoto, Malte Renz, Andrew Askew, R. L. Lander, G. De Lorenzo, A. Savoy-Navarro, Allan G Clark, Roger Moore, D. O. Litvintsev, S. Söldner-Rembold, A. Anastassov, G. Giurgiu, L. Sartori, Sooran Kim, O. Poukhov, A. Jonckheere, H. E. Fisk, P. Lebrun, M. N. Mondragon, I. Hall, A. Lobodenko, Wolfgang Wagner, Liang Li, J. C. Yun, J. Lueck, Stephen Wimpenny, S. Carrillo, J. Backusmayes, Martin Grunewald, Nicola D'Ascenzo, J. A. Appel, P. H. Beauchemin, M. Heck, D. Beecher, Peter McIntyre, G. Pauletta, M. Martínez, J. Patrick, E. Strauss, Guennadi Borissov, M. Jones, C. Pagliarone, D. Menezes, Intae Yu, Oliver Stelzer-Chilton, Th Muller, D. W. Jang, R. Van Kooten, B. Y. Han, I. Heredia-De La Cruz, Michael L. Norman, Yongsun Kim, Lev Dudko, Milos Lokajicek, D. Karmanov, M. M. Deninno, Markus Wobisch, R. Magaña-Villalba, S. W. Cho, G. Obrant, B. Whitehouse, S. Y. Jun, Julia Thom, W. C. Fisher, Adrian Buzatu, V. Boisvert, Daria Zieminska, Suneel Dutt, J. E. Kim, Aran Garcia-Bellido, M. D. Corcoran, S. Cabrera, D. E. Pellett, M. Binkley, R. D. Schamberger, M. Corbo, Y. C. Chen, F. Guo, A. J. Martin, C. Vellidis, Darien Wood, Y. Shon, D. K. Cho, T. R. Wyatt, E. Brubaker, Shabnam Jabeen, S. De Cecco, A. Dubey, G. Grenier, Hwi Dong Yoo, Zdenek Hubacek, L. Santi, A. Alton, Meng Wang, Neeti Parashar, L. Pondrom, E. Wicklund, Christoph Paus, C. P. Buszello, S. Hou, A. Das, M. Sosebee, A. Manousakis-Katsikakis, Emily Nurse, M. Merkin, L. Han, Giorgio Chiarelli, A. Rahaman, J. Huston, J. D. Lewis, Yuehong Xie, T. Scanlon, S. Kermiche, W. H. Chung, M. Rominsky, L. Brigliadori, V. M. Abazov, D. Buchholz, I. Ripp-Baudot, R. McNulty, M. Hare, M. Tecchio, A. Gessler, Helio Nogima, I. Razumov, S. Blessing, M. Zielinski, V. Rusu, A. Elagin, Vyacheslav Krutelyov, G. S. Muanza, Jay Dittmann, W. Ashmanskas, D. Hirschbuehl, H. C. Fang, Frederic Deliot, Michele Gallinaro, G. Savage, Peter Wittich, A. Napier, A. Meyer, Scott Snyder, J. Hays, S. Tokar, Suman Bala Beri, C.S. Johnson, G. Sajot, V. Hynek, Robert Hirosky, Alberto Annovi, P. Murat, Y. Hu, D. J. Cox, A. Di Canto, V. Khotilovich, Y. Seiya, O. Atramentov, Elizaveta Shabalina, M. Lancaster, G. Alkhazov, Y. Zheng, Jian Tang, L. Oakes, A. Gresele, Y. N. Kharzheev, A. Varganov, Sudhir Malik, E. G. Zverev, M. Vidal, Ia Iashvili, G. Manca, P. Roy, Raymond Brock, Robin Erbacher, M. Datta, R. Beuselinck, C. Cuenca Almenar, Javier Cuevas, Jean-Arcady Meyer, J. Mülmenstädt, D. V. Bandurin, S. Greder, Y. W. Liu, Iain Alexander Bertram, Virgil E Barnes, M. Padilla, L. Bagby, M. S. Rangel, Jahred Adelman, Jane Nachtman, Graham Wilson, Sergio F Novaes, S. Hossain, B. Jayatilaka, Kyung-Suk Cho, R. E. Hughes, P. Rich, T. Rodriguez, D. Gillberg, H. Wolfe, B. Sanghi, Suyong Choi, J. Parsons, G. Velev, J. M. Hauptman, Cecilia Elena Gerber, V. M. Podstavkov, G. Chlachidze, Michael Rijssenbeek, S. Zelitch, Jeannine Wagner-Kuhr, M. A. Strang, Brajesh C Choudhary, D. Lucchesi, Bernd Stelzer, S. Tkaczyk, F. Vázquez, P. Svoisky, C. Zeitnitz, J. Yamaoka, Arnulf Quadt, Petar Maksimovic, A. Juste, E. De La Cruz-Burelo, A. Attal, E. Pueschel, T. Wright, S. Grinstein, Todd Adams, K. M. Chan, A. S. Ito, A. Melnitchouk, T. Aaltonen, J. Antos, Thorsten Chwalek, Elemer Nagy, C. J. Lin, W. M. Van Leeuwen, M. Fortner, Sarah Catherine Eno, Horst Severini, Tiehui Liu, Rodolfo Carosi, A. Barbaro-Galtieri, R. G. Feild, J. S. Suh, K. Osterberg, D. Mietlicki, S. Richter, Michal Kreps, T. Nunnemann, B. Baldin, Corrinne Mills, G. P. Yeh, C. S. Moon, M. J. Kim, S. J. Park, A. Menzione, M. E. Convery, E. Palencia, J. C. Cully, Aron Soha, M. Cordelli, G. Busetto, Brian L Winer, G. Ginther, G. Bauer, G. Golovanov, M. J. Morello, F. D. Snider, J. Y. Han, N. Giokaris, Junjie Zhu, S. Wolbers, V. V. Tokmenin, L. S. Vertogradov, R. J. Miller, J. Martínez-Ortega, M. Weinberger, Bjoern Penning, G. Facini, M. Kurata, Andrea Castro, G. D. Alexeev, Flera Rizatdinova, M. Milnik, U. Husemann, B. Álvarez González, V. N. Evdokimov, A. Bridgeman, K. Sliwa, S. Klimenko, Evelyn Thomson, C. Deluca, Fabrizio Scuri, D. Wicke, Dennis Stephen Mackin, Andrew Brandt, Kirti Ranjan, Jianming Qian, J. L. Gimmell, V. V. Lipaev, J. Lellouch, H. A. Neal, Ivan-Kresimir Furic, Y. D. Oh, D. Bauer, M. C. Cousinou, V. A. Giakoumopoulou, Carsten Hensel, A. Mukherjee, C. Belanger-Champagne, B. S. Acharya, Nicola Turini, J. Pursley, H. Nilsen, R. G. Wagner, B. Spurlock, G. Piacentino, M. Buehler, A. T. Laasanen, Zeno Dixon Greenwood, Y. Arnoud, Richard B. Lipton, D. W. Gerdes, Pedro G Mercadante, Ph Gris, T. Kuhr, P. Houben, M. H. Kirby, H. Miyake, F. Happacher, Kristian Harder, Dario Bisello, G. Gutierrez, M. D'Errico, Joe Kroll, B. C.K. Casey, X. Wu, T. A. Schwarz, A. Bhatti, P. A. Kasper, Hugh Williams, M. P. Sanders, Ignacio Redondo, Hyun-Chul Kim, Yurii Maravin, Vladimir Gavrilov, A. Aurisano, Teresa Rodrigo, D. Boline, K. Chung, Peter Love, Pushpalatha C Bhat, W. Geng, N. Ranjan, R. Jesik, S. Carron, L. Demortier, S. Dube, S. H. Oh, M. A. Schmidt, Mark Richard James Williams, R. Bernhard, W. E. Cooper, P. N. Dong, D. Khatidze, Giovanni Bellettini, M. Rossi, J. Slaunwhite, D. Cutts, J. T. Linnemann, David T. Johnston, Gordon Watts, Daniela Bortoletto, O. Mundal, K. Yip, P. E. Karchin, P. Haefner, Roman Lysak, M. Iori, C. Bromberg, Duncan Carlsmith, K. A. Johns, Anna Goussiou, Elisabetta Pianori, A. V. Kotwal, Gregorio Bernardi, Andrea Bocci, D. Denisov, X. Zhang, A. Scribano, D. Onoprienko, T. J. Phillips, A. A. Paramanov, K. Ebina, G. Otero y Garzon, M. Trovato, M. Cavalli-Sforza, W. M. Yao, Aaron Dominguez, Jochen Jens Heinrich, W. Geist, Tiefu Zhao, S. Budd, G. A. Thompson, Je Jung, S. W. Youn, P. Polozov, Koji Nakamura, Arnaud Duperrin, S. Neubauer, S. Y. Tsai, Sharon Hagopian, S. Torre, S. Amerio, S. Zucchelli, A. K.A. Maciel, W. Johnson, K. T. Pitts, A. Simonenko, V. Sirotenko, S. Wilbur, J. K. Kraus, J. Weinelt, Greg Landsberg, I. Suslov, K. Herner, N. Khalatyan, S. Yacoob, A. Schmidt, B. Hoeneisen, Lee Sawyer, Maria Agnese Ciocci, A. Mitra, Michael Schmitt, N. Kimura, Hal Evans, Thomas Ferbel, M. Prewitt, Cristina Galea, M. Hartz, T. Wakisaka, Lars Sonnenschein, Zhanqiang Liu, M. Cooke, Tommaso Dorigo, S. Hewamanage, Sinead Farrington, M. P. Schmidt, P. L.M. Podesta-Lerma, D. H. Kim, V. Kaushik, J. F. Bartlett, J. Lys, Stephan Lammel, Lucio Cerrito, R. E. Blair, Jong-Sung Yu, F. Rimondi, Pavol Bartos, N. Ershaidat, E. E. Boos, E. E. Schmidt, Marco Verzocchi, Theodoros Christoudias, S. Lami, Emanuela Barberis, Avraham Yagil, Dean Hidas, Heriberto Castilla-Valdez, J. Morlock, S. Seidel, R. Unalan, L. Stutte, A. Canepa, C. Ferrazza, C. P. Marino, G. Flanagan, A. N. Sisakyan, E. Rogers, P. Totaro, R. Nayyar, Robert Kehoe, Maxwell Chertok, A. Patwa, W. Badgett, J. Clutter, Md. Naimuddin, V. Papadimitriou, M. Kirsch, A.S. Dyshkant, D. Smirnov, George Alverson, K. Tollefson, E. J. Jeon, A. Sukhanov, R. Vilar, N. Krumnack, P. K. Teng, K. S. McFarland, Federico Sforza, Mark Owen, S. Somalwar, Deepak Kar, R. Piegaia, V. V. Glagolev, MarioPaolo Giordani, S. J. De Jong, K. Soustruznik, Ashok Kumar, E. Carrera, I. Bizjak, J. Conway, E. Lee, M. Stanitzki, A. Papaikonomou, M. E. Mattson, M. Arov, Andre Sopczak, G. Hesketh, B. Brau, D. Hedin, Brad Abbott, P. Catastini, T. Tomura, A. Evdokimov, S. Pagan Griso, Robert Snihur, Marcia Begalli, Ulysses Grundler, C. I. Ciobanu, R. L. Wagner, Jiri Kvita, D. Gerbaudo, D. Lam, S. Z. Shalhout, Victoria Jane Martin, R. Martínez-Ballarín, Thomas Peiffer, Alexander Grohsjean, Phillip Gutierrez, Pierre Petroff, A. Golossanov, Shih-Fu Chang, Rainer Wallny, M. Demarteau, Andreas Warburton, Satoru Uozumi, U. Bassler, Andrew Beretvas, R. F. Harr, M. Mathis, Meenakshi Narain, A. Pronko, Arie Bodek, S. Moed, P. J. Van Den Berg, Lev Uvarov, Marc Besancon, D. Benjamin, K. Goulianos, J. Snow, M. Abolins, S. Rolli, Elliott Cheu, T. Schliephake, A. Taffard, Victor Daniel Elvira, Marvin Johnson, K. Peters, Sung Keun Park, Massimo Casarsa, Sergey Burdin, S. Robinson, J. Deng, Gregory R Snow, A. A. Shchukin, P. Movilla Fernandez, M. Shimojima, J. P. Chou, Heimo Saarikko, A. Sedov, M. A. Carrasco-Lizarraga, M. Feindt, M. Eads, Y. Takeuchi, Regina Demina, J. Strologas, C. Calancha, B. Di Ruzza, P. Sinervo, P. Schlabach, S. P. Denisov, V. Parihar, Frank Fiedler, A. L. Lyon, Philip Baringer, F. Garberson, H. W. Kim, N. K. Mondal, Mauro Dell'Orso, Tulika Bose, S. Pashapour, A. Apresyan, E. Kajfasz, Song-Ming Wang, A. V. Kozelov, Samuel Calvet, H. T. Diehl, T. A. Bolton, P. Neustroev, V. Saveliev, F. Azfar, R. Culbertson, C. Haber, O. Norniella, V. V. Shary, A. Boehnlein, M. Lindgren, J. Piper, S. Banerjee, E. Vataga, Dorothee Schaile, Michael Mulhearn, R. St. Denis, J. R. Smith, G. B. Yu, J. Ellison, W. Ketchum, D. Hare, G. Williams, D. Edmunds, Igor Volobouev, Jeroen Hegeman, J. Linacre, T. Moulik, P. de Barbaro, Avto Kharchilava, C. A. Cox, Fumihiko Ukegawa, Sa. Jain, A. Penzo, S. Fuess, K. K. Joo, T. Kurca, Marc Weber, B. Parks, James Russ, Kohei Yorita, T. Hoang, Franco Bedeschi, R. Otec, D. Glenzinski, Alexander Khanov, Jonas Strandberg, P. B. Renton, J. Orduna, S. S. Yu, Tomoko Yoshida, A. B. Wicklund, D. Jamin, Grigory Safronov, S. Chevalier-Théry, J. Thome, S. Chakrabarti, V. Cavaliere, D. Waters, M. Hohlfeld, P. N. Ratoff, D. Toback, Y. Peters, P. Vint, Zhenyu Ye, Maksym Titov, Yuri Gershtein, N. P. Kulkarni, Y. Zeng, P. Rubinov, Daniel Duggan, Ernest Aguilo, Tara Shears, Hua-Lei Yin, A. V. Popov, W. C. Wester, M. Campbell, D. Stentz, A. Loginov, S. Desai, T. Dorland, D. Dagenhart, M. Jaffré, Gustaaf Brooijmans, M. Rescigno, L. S. Ancu, Petr Vokac, Joseph Haley, J. Warchol, P. Lujan, P. Garosi, Christophe Royon, V. Ramakrishnan, Alexander Leflat, J. Asaadi, Y. S. Chung, E. Camacho-Pérez, C. Wolfe, P. Barria, E. James, B. Calpas, L. Lovas, Reinhard Schwienhorst, S. Behari, Luca Scodellaro, H. D. Wahl, Alexander Kupco, F. Badaud, K. L. Byrum, P. Giromini, Andrew White, Gilvan Alves, L. Sexton-Kennedy, R. Forrest, I. Katsanos, Anna Zanetti, G. Compostella, Maxim Goncharov, N. Huske, N. Parua, D. Vilanova, Randy Ruchti, Joe Incandela, L. Nodulman, J. N. Bellinger, M. D'onofrio, T. Miao, P. Mättig, X. B. Bu, D. Chokheli, R. Kephart, K. Gibson, M. M. Meijer, L. Ristori, N. S. Lockyer, Roberto Rossin, A. Boveia, Aidan Robson, Kevin Burkett, T. Yasuda, R. Illingworth, N. Moggi, D. Errede, S. Beale, Chuan-Ming Liu, G. Punzi, John Hobbs, Yuji Enari, Y. Kato, L. Zivkovic, J. Guimaraes Da Costa, J. Barreto, D. Tonelli, Alexey Ferapontov, M. Wetstein, I. V. Gorelov, H. S. Budd, M. A. Houlden, Andrew Mehta, Jacobo Konigsberg, L. Duflot, J. K. Lim, Stefano Camarda, Frank Chlebana, F. Ptohos, B. Åsman, L. Pinera, A. P. Heinson, S. Malde, M. A. Pleier, P. Renkel, P. Mehtala, M. Giunta, A. Artikov, S. Schlobohm, H. Greenlee, D. M. Strom, Matthew Herndon, E. Lipeles, M. K. Jha, A. Bross, Christopher George Tully, M. Hussein, Benjamin Kilminster, Serban Protopopescu, Barry Blumenfeld, M. Aoki, Andy Haas, G. Weber, D. Chakraborty, J. S. Lee, Don Lincoln, Erich Varnes, S. Shiraishi, S. Kwang, M. Hurwitz, S. R. Hahn, M. Vesterinen, N. Osman, A. Deisher, T. R. Junk, Patrick Slattery, A. Chandra, J. Yoh, D. A. Stoyanova, C. L. McGivern, Gervasio Gomez, Michael Begel, Andrey Korytov, Eduardo De Moraes Gregores, Luiz Mundim, R. Takashima, T. H. Burnett, Amitabh Lath, Anna Sfyrla, Paola Giannetti, B. A. Barnett, Giorgio Apollinari, J. A. Benitez, Teruki Kamon, P. Mazzanti, Craig Blocker, Ulrich Heintz, D. Cauz, Kaori Maeshima, P. K. Mal, H. S. Lee, Frank Filthaut, Paolo Mastrandrea, M. Diesburg, P. Wilson, J. E. Garcia, A. Tanasijczuk, T. Davies, C. S. Hill, Sandra Leone, S. Uvarov, B. Quinn, W. K. Sakumoto, C. Schwanenberger, Alice Bean, C. Grosso-Pilcher, I. Oksuzian, N. Goldschmidt, Volker Buescher, Peter Bussey, T. Gadfort, Maria Elena Pol, Kai Yi, C. M. Ginsburg, R. Roser, Ivan Vila, P. F. Shepard, B. Rutherford, Alexander Ivanov, N. Van Remortel, S. C. Hsu, Reisaburo Tanaka, Guido Volpi, Nikos Varelas, O. González, Bing Zhou, Luis Mendoza, R. K. Shivpuri, S. Donati, Kenichi Hatakeyama, M. Franklin, D. R. Claes, Gavin Davies, Philippe Calfayan, Itsuo Nakano, Harald Fox, S. M. Lietti, Y. Scheglov, J. C. Freeman, Kaushik De, A. Ruiz, Giuseppe Latino, Alan Garfinkel, Jan Stark, Fabrizio Margaroli, S. Errede, Maiko Takahashi, Henry Lubatti, J. Cammin, I. A. Vasilyev, Vipin Bhatnagar, A. Cerri, R. Partridge, Markus Frank, P. M. Tuts, D. MacQueen, H. Gerberich, Kenneth Bloom, V. L. Malyshev, Mark Neubauer, R. Orava, G. Lungu, R. D. Field, D. J. Kong, W. C. Yang, Department of Physics, Helsinki Institute of Physics, CDF Collaboration, D0 Collaboration, Laboratoire de Physique Subatomique et de Cosmologie (LPSC), Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Joseph Fourier - Grenoble 1 (UJF)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Physique Corpusculaire - Clermont-Ferrand (LPC), Université Blaise Pascal - Clermont-Ferrand 2 (UBP)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Centre de Physique des Particules de Marseille (CPPM), Aix Marseille Université (AMU)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Laboratoire de Physique Nucléaire et de Hautes Énergies (LPNHE), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Pierre et Marie Curie - Paris 6 (UPMC), Laboratoire de l'Accélérateur Linéaire (LAL), Centre National de la Recherche Scientifique (CNRS)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris-Sud - Paris 11 (UP11), Institut de Physique Nucléaire de Lyon (IPNL), Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3), CDF, D0, Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Institut Polytechnique de Grenoble - Grenoble Institute of Technology-Centre National de la Recherche Scientifique (CNRS), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud - Paris 11 (UP11)-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Physique Nucléaire et de Physique des Particules du CNRS (IN2P3)-Centre National de la Recherche Scientifique (CNRS), Universidad de Cantabria, T. AALTONEN, V. M. ABAZOV, B. ABBOTT, M. ABOLINS, B. S. ACHARYA, M. ADAMS, T. ADAMS, J. ADELMAN, E. AGUILO, G. D. ALEXEEV, G. ALKHAZOV, A. ALTON, B. ÁLVAREZ GONZÁLEZ, G. ALVERSON, G. A. ALVES, S. AMERIO, D. AMIDEI, A. ANASTASSOV, L. S. ANCU, A. ANNOVI, J. ANTOS, M. AOKI, G. APOLLINARI, J. APPEL, A. APRESYAN, T. ARISAWA, Y. ARNOUD, M. AROV, A. ARTIKOV, J. ASAADI, W. ASHMANSKAS, A. ASKEW, B. ÅSMAN, O. ATRAMENTOV, A. ATTAL, A. AURISANO, C. AVILA, F. AZFAR, J. BACKUSMAYES, F. BADAUD, W. BADGETT, L. BAGBY, B. BALDIN, D. V. BANDURIN, S. BANERJEE, A. BARBARO-GALTIERI, E. BARBERIS, A.-F. BARFUSS, P. BARINGER, V. E. BARNES, B. A. BARNETT, J. BARRETO, P. BARRIAC,A, J. F. BARTLETT, P. BARTOS, U. BASSLER, D. BAUER, G. BAUER, S. BEALE, A. BEAN, P.-H. BEAUCHEMIN, F. BEDESCHI, D. BEECHER, M. BEGALLI, M. BEGEL, S. BEHARI, C. BELANGER-CHAMPAGNE, L. BELLANTONI, G. BELLETTINI, J. BELLINGER, J. A. BENITEZ, D. BENJAMIN, A. BERETVAS, S. B. BERI, G. BERNARDI, R. BERNHARD, I. BERTRAM, M. BESANÇON, R. BEUSELINCK, V. A. BEZZUBOV, P. C. BHAT, V. BHATNAGAR, A. BHATTI, M. BINKLEY, D. BISELLO, I. BIZJAK, R. E. BLAIR, G. BLAZEY, S. BLESSING, C. BLOCKER, K. BLOOM, B. BLUMENFELD, A. BOCCI, A. BODEK, A. BOEHNLEIN, V. BOISVERT, D. BOLINE, T. A. BOLTON, E. E. BOOS, G. BORISSOV, D. BORTOLETTO, T. BOSE, J. BOUDREAU, A. BOVEIA, A. BRANDT, B. BRAU, A. BRIDGEMAN, L. BRIGLIADORI, R. BROCK, C. BROMBERG, G. BROOIJMANS, A. BROSS, D. BROWN, E. BRUBAKER, X. B. BU, D. BUCHHOLZ, J. BUDAGOV, H. S. BUDD, S. BUDD, M. BUEHLER, V. BUESCHER, V. BUNICHEV, S. BURDIN, K. BURKETT, T. H. BURNETT, G. BUSETTO, P. BUSSEY, C. P. BUSZELLO, A. BUZATU, K. L. BYRUM, S. CABRERA, C. CALANCHA, P. CALFAYAN, B. CALPAS, S. CALVET, E. CAMACHO-PÉREZ, S. CAMARDA, J. CAMMIN, M. CAMPANELLI, M. CAMPBELL, F. CANELLI, A. CANEPA, B. CARLS, D. CARLSMITH, R. CAROSIA, M. A. CARRASCO-LIZARRAGA, E. CARRERA, S. CARRILLO, S. CARRON, B. CASAL, M. CASARSA, B. C. K. CASEY, H. CASTILLA-VALDEZ, A. CASTRO, P. CATASTINI, D. CAUZA, V. CAVALIEREC,A, M. CAVALLI-SFORZA, A. CERRI, L. CERRITO, S. CHAKRABARTI, D. CHAKRABORTY, K. M. CHAN, A. CHANDRA, S. H. CHANG, Y. C. CHEN, M. CHERTOK, E. CHEU, S. CHEVALIER-THÉRY, G. CHIARELLI, G. CHLACHIDZE, F. CHLEBANA, K. CHO, D. K. CHO, S. W. CHO, S. CHOI, D. CHOKHELI, J. P. CHOU, B. CHOUDHARY, T. CHRISTOUDIAS, K. CHUNG,I, W. H. CHUNG, Y. S. CHUNG, T. CHWALEK, S. CIHANGIR, C. I. CIOBANU, M. A. CIOCCI, D. CLAES, A. CLARK, D. CLARK, J. CLUTTER, G. COMPOSTELLA, M. E. CONVERY, J. CONWAY, M. COOKE, W. E. COOPER, M. CORBO, M. CORCORAN, M. CORDELLI, F. COUDERC, M.-C. COUSINOU, C. A. COX, D. J. COX, F. CRESCIOLI, C. CUENCA ALMENAR, J. CUEVAS, R. CULBERTSON, J. C. CULLY, D. CUTTS, M. &#262, WIOK, D. DAGENHART, N. D’ASCENZO, A. DAS, M. DATTA, G. DAVIES, T. DAVIES, K. DE, P. DE BARBARO, S. DE CECCO, A. DEISHER, S. J. DE JONG, E. DE LA CRUZ-BURELO, F. DÉLIOT, M. DELL’ORSO, G. DE LORENZO, C. DELUCA, M. DEMARTEAU, R. DEMINA, L. DEMORTIER, J. DENG, M. DENINNO, D. DENISOV, S. P. DENISOV, M. D’ERRICO, S. DESAI, K. DEVAUGHAN, A. DI CANTO, H. T. DIEHL, M. DIESBURG, B. DI RUZZA, J. R. DITTMANN, A. DOMINGUEZ, S. DONATI, P. DONG, M. D’ONOFRIO, T. DORIGO, T. DORLAND, S. DUBE, A. DUBEY, L. V. DUDKO, L. DUFLOT, D. DUGGAN, A. DUPERRIN, S. DUTT, A. DYSHKANT, M. EADS, K. EBINA, D. EDMUNDS, A. ELAGIN, J. ELLISON, V. D. ELVIRA, Y. ENARI, S. ENO, R. ERBACHER, D. ERREDE, S. ERREDE, N. ERSHAIDAT, R. EUSEBI, H. EVANS, A. EVDOKIMOV, V. N. EVDOKIMOV, G. FACINI, H. C. FANG, S. FARRINGTON, W. T. FEDORKO, R. G. FEILD, M. FEINDT, A. V. FERAPONTOV, T. FERBEL, J. P. FERNANDEZ, C. FERRAZZAD, F. FIEDLER, R. FIELD, F. FILTHAUT, W. FISHER, H. E. FISK, G. FLANAGAN, R. FORREST, M. FORTNER, H. FOX, M. J. FRANK, M. FRANKLIN, J. C. FREEMAN, S. FUESS, I. FURIC, T. GADFORT, C. F. GALEA, M. GALLINARO, J. GALYARDT, F. GARBERSON, J. E. GARCIA, A. GARCIA-BELLIDO, A. F. GARFINKEL, P. GAROSI, V. GAVRILOV, P. GAY, W. GEIST, W. GENG, D. GERBAUDO, C. E. GERBER, H. GERBERICH, D. GERDES, Y. GERSHTEIN, A. GESSLER, S. GIAGU, V. GIAKOUMOPOULOU, P. GIANNETTI, K. GIBSON, D. GILLBERG, J. L. GIMMELL, C. M. GINSBURG, G. GINTHER, N. GIOKARIS, M. GIORDANI, P. GIROMINI, M. GIUNTA, G. GIURGIU, V. GLAGOLEV, D. GLENZINSKI, M. GOLD, N. GOLDSCHMIDT, A. GOLOSSANOV, G. GOLOVANOV, B. GÓMEZ, G. GOMEZ, G. GOMEZ-CEBALLOS, M. GONCHAROV, O. GONZÁLEZ, I. GORELOV, A. T. GOSHAW, K. GOULIANOS, A. GOUSSIOU, P. D. GRANNIS, S. GREDER, H. GREENLEE, Z. D. GREENWOOD, E. M. GREGORES, G. GRENIER, A. GRESELE, S. GRINSTEIN, PH. GRIS, J.-F. GRIVAZ, A. GROHSJEAN, C. GROSSO-PILCHER, R. C. GROUP, U. GRUNDLER, S. GRÜNENDAHL, M. W. GRÜNEWALD, J. GUIMARAES DA COSTA, Z. GUNAY-UNALAN, F. GUO, J. GUO, G. GUTIERREZ, P. GUTIERREZ, A. HAAS, C. HABER, P. HAEFNER, S. HAGOPIAN, S. R. HAHN, J. HALEY, E. HALKIADAKIS, I. HALL, B.-Y. HAN, J. Y. HAN, L. HAN, F. HAPPACHER, K. HARA, K. HARDER, D. HARE, M. HARE, A. HAREL, R. F. HARR, M. HARTZ, K. HATAKEYAMA, J. M. HAUPTMAN, C. HAYS, J. HAYS, T. HEBBEKER, M. HECK, D. HEDIN, J. G. HEGEMAN, J. HEINRICH, A. P. HEINSON, U. HEINTZ, C. HENSEL, I. HEREDIA-DE LA CRUZ, M. HERNDON, K. HERNER, G. HESKETH, J. HEUSER, S. HEWAMANAGE, D. HIDAS, M. D. HILDRETH, C. S. HILL,§, R. HIROSKY, D. HIRSCHBUEHL, T. HOANG, J. D. HOBBS, A. HOCKER, B. HOENEISEN, M. HOHLFELD, S. HOSSAIN, P. HOUBEN, S. HOU, M. HOULDEN, S.-C. HSU, Y. HU, Z. HUBACEK, R. E. HUGHES, M. HURWITZ, U. HUSEMANN, N. HUSKE, M. HUSSEIN, J. HUSTON, V. HYNEK, I. IASHVILI, R. ILLINGWORTH, J. INCANDELA, G. INTROZZI, M. IORI, A. S. ITO, A. IVANOV,K, S. JABEEN, M. JAFFRÉ, S. JAIN, E. JAMES, D. JAMIN, D. JANG, B. JAYATILAKA, E. J. JEON, R. JESIK, M. K. JHA, S. JINDARIANI, K. JOHNS, C. JOHNSON, M. JOHNSON, W. JOHNSON, D. JOHNSTON, A. JONCKHEERE, M. JONES, P. JONSSON, K. K. JOO, S. Y. JUN, J. E. JUNG, T. R. JUNK, A. JUSTE, E. KAJFASZ, T. KAMON, P. E. KARCHIN, D. KAR, D. KARMANOV, P. A. KASPER, Y. KATO, I. KATSANOS, V. KAUSHIK, R. KEHOE, R. KEPHART, S. KERMICHE, W. KETCHUM, J. KEUNG, N. KHALATYAN, A. KHANOV, A. KHARCHILAVA, Y. N. KHARZHEEV, D. KHATIDZE, V. KHOTILOVICH, B. KILMINSTER, D. H. KIM, H. S. KIM, H. W. KIM, J. E. KIM, M. J. KIM, S. B. KIM, S. H. KIM, Y. K. KIM, N. KIMURA, M. H. KIRBY, L. KIRSCH, M. KIRSCH, S. KLIMENKO, J. M. KOHLI, K. KONDO, D. J. KONG, J. KONIGSBERG, A. KORYTOV, A. V. KOTWAL, A. V. KOZELOV, J. KRAUS, M. KREPS, J. KROLL, D. KROP, N. KRUMNACK, M. KRUSE, V. KRUTELYOV, T. KUHR, N. P. KULKARNI, A. KUMAR, A. KUPCO, M. KURATA, T. KUR&#269, A, V. A. KUZMIN, J. KVITA, S. KWANG, A. T. LAASANEN, D. LAM, S. LAMIA, S. LAMMEL, S. LAMMERS, M. LANCASTER, R. L. LANDER, G. LANDSBERG, K. LANNON,P, A. LATH, G. LATINO, I. LAZZIZZERA, P. LEBRUN, T. LECOMPTE, E. LEE, H. S. LEE, H. S. LEE, J. S. LEE, S. W. LEE, W. M. LEE, A. LEFLAT, J. LELLOUCH, S. LEONEA, J. D. LEWIS, L. LI, Q. Z. LI, S. M. LIETTI, J. K. LIM, J. LINACRE, D. LINCOLN, C.-J. LIN, M. LINDGREN, J. LINNEMANN, V. V. LIPAEV, E. LIPELES, R. LIPTON, A. LISTER, D. O. LITVINTSEV, C. LIU, T. LIU, Y. LIU, Z. LIU, A. LOBODENKO, N. S. LOCKYER, A. LOGINOV, M. LOKAJICEK, L. LOVAS, P. LOVE, H. J. LUBATTI, D. LUCCHESI, J. LUECK, P. LUJAN, P. LUKENS, R. LUNA-GARCIA, G. LUNGU, A. L. LYON, R. LYSAK, J. LYS, A. K. A. MACIEL, D. MACKIN, D. MACQUEEN, R. MADRAK, K. MAESHIMA, R. MAGAÑA-VILLALBA, K. MAKHOUL, P. MAKSIMOVIC, P. K. MAL, S. MALDE, S. MALIK, S. MALIK, V. L. MALYSHEV, G. MANCA, A. MANOUSAKIS-KATSIKAKIS, Y. MARAVIN, F. MARGAROLI, C. MARINO, C. P. MARINO, A. MARTIN, V. MARTIN,E, M. MARTÍNEZ, R. MARTÍNEZ-BALLARÍN, J. MARTÍNEZ-ORTEGA, P. MASTRANDREA, M. MATHIS, P. MÄTTIG, M. E. MATTSON, P. MAZZANTI, R. MCCARTHY, K. S. MCFARLAND, C. L. MCGIVERN, P. MCINTYRE, R. MCNULTY, A. MEHTA, P. MEHTALA, M. M. MEIJER, A. MELNITCHOUK, L. MENDOZA, D. MENEZES, A. MENZIONE, P. G. MERCADANTE, M. MERKIN, C. MESROPIAN, A. MEYER, J. MEYER, T. MIAO, D. MIETLICKI, N. MILADINOVIC, R. MILLER, C. MILLS, M. MILNIK, A. MITRA, G. MITSELMAKHER, H. MIYAKE, S. MOED, N. MOGGI, N. K. MONDAL, M. N. MONDRAGON, C. S. MOON, R. MOORE, M. J. MORELLO, J. MORLOCK, T. MOULIK, P. MOVILLA FERNANDEZ, G. S. MUANZA, A. MUKHERJEE, M. MULHEARN, TH. MULLER, J. MÜLMENSTÄDT, O. MUNDAL, L. MUNDIM, P. MURAT, M. MUSSINI, J. NACHTMAN,I, Y. NAGAI, J. NAGANOMA, E. NAGY, M. NAIMUDDIN, K. NAKAMURA, I. NAKANO, A. NAPIER, M. NARAIN, R. NAYYAR, H. A. NEAL, J. P. NEGRET, J. NETT, C. NEU, M. S. NEUBAUER, S. NEUBAUER, P. NEUSTROEV, J. NIELSEN, H. NILSEN, L. NODULMAN, H. NOGIMA, M. NORMAN, O. NORNIELLA, S. F. NOVAES, T. NUNNEMANN, E. NURSE, L. OAKES, G. OBRANT, S. H. OH, Y. D. OH, I. OKSUZIAN, T. OKUSAWA, D. ONOPRIENKO, R. ORAVA, J. ORDUNA, N. OSMAN, J. OSTA, K. OSTERBERG, R. OTEC, G. J. OTERO Y GARZÓN, M. OWEN, M. PADILLA, P. PADLEY, S. PAGAN GRISOB,A, C. PAGLIARONE, E. PALENCIA, M. PANGILINAN, V. PAPADIMITRIOU, A. PAPAIKONOMOU, A. A. PARAMANOV, N. PARASHAR, V. PARIHAR, S.-J. PARK, S. K. PARK, B. PARKS, J. PARSONS, R. PARTRIDGE, N. PARUA, S. PASHAPOUR, J. PATRICK, A. PATWA, G. PAULETTA, M. PAULINI, C. PAUS, T. PEIFFER, D. E. PELLETT, B. PENNING, A. PENZO, M. PERFILOV, K. PETERS, Y. PETERS, P. PÉTROFF, T. J. PHILLIPS, G. PIACENTINO, E. PIANORI, R. PIEGAIA, L. PINERA, J. PIPER, K. PITTS, C. PLAGER, M.-A. PLEIER, P. L. M. PODESTA-LERMA, V. M. PODSTAVKOV, M.-E. POL, P. POLOZOV, L. PONDROM, A. V. POPOV, K. POTAMIANOS, O. POUKHOV, M. PREWITT, D. PRICE, F. PROKOSHIN,U, A. PRONKO, S. PROTOPOPESCU, F. PTOHOS, E. PUESCHEL, G. PUNZI, J. PURSLEY, J. QIAN, A. QUADT, B. QUINN, J. RADEMACKER,§, A. RAHAMAN, V. RAMAKRISHNAN, M. S. RANGEL, K. RANJAN, N. RANJAN, P. N. RATOFF, I. RAZUMOV, I. REDONDO, P. RENKEL, P. RENTON, M. RENZ, M. RESCIGNO, P. RICH, S. RICHTER, M. RIJSSENBEEK, F. RIMONDI, I. RIPP-BAUDOT, L. RISTORIA, F. RIZATDINOVA, S. ROBINSON, A. ROBSON, T. RODRIGO, T. RODRIGUEZ, E. ROGERS, S. ROLLI, M. ROMINSKY, R. ROSER, M. ROSSIA, R. ROSSIN, P. ROY, C. ROYON, P. RUBINOV, R. RUCHTI, A. RUIZ, J. RUSS, V. RUSU, B. RUTHERFORD, H. SAARIKKO, A. SAFONOV, G. SAFRONOV, G. SAJOT, W. K. SAKUMOTO, A. SÁNCHEZ-HERNÁNDEZ, M. P. SANDERS, B. SANGHI, L. SANTI, L. SARTORIA, K. SATO, G. SAVAGE, V. SAVELIEV, A. SAVOY-NAVARRO, L. SAWYER, T. SCANLON, D. SCHAILE, R. D. SCHAMBERGER, Y. SCHEGLOV, H. SCHELLMAN, P. SCHLABACH, T. SCHLIEPHAKE, S. SCHLOBOHM, A. SCHMIDT, E. E. SCHMIDT, M. A. SCHMIDT, M. P. SCHMIDT, M. SCHMITT, C. SCHWANENBERGER, T. SCHWARZ, R. SCHWIENHORST, L. SCODELLARO, A. SCRIBANO, F. SCURIA, A. SEDOV, S. SEIDEL, Y. SEIYA, J. SEKARIC, A. SEMENOV, H. SEVERINI, L. SEXTON-KENNEDY, F. SFORZA, A. SFYRLA, E. SHABALINA, S. Z. SHALHOUT, V. SHARY, A. A. SHCHUKIN, T. SHEARS, P. F. SHEPARD, M. SHIMOJIMA,O, S. SHIRAISHI, R. K. SHIVPURI, M. SHOCHET, Y. SHON, I. SHREYBER, V. SIMAK, A. SIMONENKO, P. SINERVO, V. SIROTENKO, A. SISAKYAN, P. SKUBIC, P. SLATTERY, A. J. SLAUGHTER, J. SLAUNWHITE, K. SLIWA, D. SMIRNOV, J. R. SMITH, F. D. SNIDER, R. SNIHUR, G. R. SNOW, J. SNOW, S. SNYDER, A. SOHA, S. SÖLDNER-REMBOLD, S. SOMALWAR, L. SONNENSCHEIN, A. SOPCZAK, V. SORIN, M. SOSEBEE, K. SOUSTRUZNIK, B. SPURLOCK, P. SQUILLACIOTIC,A, M. STANITZKI, J. STARK, R. ST. DENIS, B. STELZER, O. STELZER-CHILTON, D. STENTZ, V. STOLIN, D. A. STOYANOVA, J. STRANDBERG, M. A. STRANG, E. STRAUSS, M. STRAUSS, R. STRÖHMER, J. STROLOGAS, D. STROM, G. L. STRYCKER, L. STUTTE, J. S. SUH, A. SUKHANOV, I. SUSLOV, P. SVOISKY, A. TAFFARD, M. TAKAHASHI, R. TAKASHIMA, Y. TAKEUCHI, R. TANAKA, A. TANASIJCZUK, J. TANG, W. TAYLOR, M. TECCHIO, P. K. TENG, J. THOM, J. THOME, G. A. THOMPSON, E. THOMSON, B. TILLER, P. TIPTON, M. TITOV, S. TKACZYK, D. TOBACK, S. TOKAR, V. V. TOKMENIN, K. TOLLEFSON, T. TOMURA, D. TONELLI, S. TORRE, D. TORRETTA, P. TOTARO, M. TROVATO, S.-Y. TSAI, D. TSYBYCHEV, P. TTITO-GUZMÁN, B. TUCHMING, Y. TU, C. TULLY, N. TURINI, P. M. TUTS, F. UKEGAWA, R. UNALAN, S. UOZUMI, L. UVAROV, S. UVAROV, S. UZUNYAN, P. J. VAN DEN BERG, R. VAN KOOTEN, W. M. VAN LEEUWEN, N. VAN REMORTEL, N. VARELAS, A. VARGANOV, E. W. VARNES, I. A. VASILYEV, E. VATAGAD,A, F. VÁZQUEZ,H, G. VELEV, C. VELLIDIS, P. VERDIER, L. S. VERTOGRADOV, M. VERZOCCHI, M. VESTERINEN, M. VIDAL, I. VILA, D. VILANOVA, R. VILAR, P. VINT, M. VOGEL, P. VOKAC, I. VOLOBOUEV,S, G. VOLPI, P. WAGNER, R. G. WAGNER, R. L. WAGNER, W. WAGNER,W, J. WAGNER-KUHR, H. D. WAHL, T. WAKISAKA, R. WALLNY, M. H. L. S. WANG, S. M. WANG, A. WARBURTON, J. WARCHOL, D. WATERS, G. WATTS, M. WAYNE, G. WEBER, M. WEBER, M. WEINBERGER, J. WEINELT, W. C. WESTER, III, M. WETSTEIN, A. WHITE, B. WHITEHOUSE, D. WHITESON, D. WICKE, A. B. WICKLUND, E. WICKLUND, S. WILBUR, G. WILLIAMS, H. H. WILLIAMS, M. R. J. WILLIAMS, G. W. WILSON, P. WILSON, S. J. WIMPENNY, B. L. WINER, P. WITTICH, M. WOBISCH, S. WOLBERS, C. WOLFE, H. WOLFE, D. R. WOOD, T. WRIGHT, X. WU, F. WÜRTHWEIN, T. R. WYATT, Y. XIE, C. XU, S. YACOOB, A. YAGIL, R. YAMADA, K. YAMAMOTO, J. YAMAOKA, U. K. YANG,M, W.-C. YANG, Y. C. YANG, W. M. YAO, T. YASUDA, Y. A. YATSUNENKO, Z. YE, G. P. YEH, K. YI,I, H. YIN, K. YIP, J. YOH, H. D. YOO, K. YORITA, T. YOSHIDA,F, S. W. YOUN, G. B. YU, I. YU, J. YU, S. S. YU, J. C. YUN, A. ZANETTIA, C. ZEITNITZ, S. ZELITCH, Y. ZENG, X. ZHANG, T. ZHAO, Y. ZHENG, B. ZHOU, J. ZHU, M. ZIELINSKI, D. ZIEMINSKA, L. ZIVKOVIC, S. ZUCCHELLI, V. ZUTSHI, E. G. ZVEREV, D0 (Tevatron, IHEF, IOP, FNWI), Universidad de Buenos Aires, Centro Brasileiro de Pesquisas Físicas, Universidade do Estado do Rio de Janeiro (UERJ), Universidade Federal do ABC (UFABC), Universidade Estadual Paulista (UNESP), McGill University, Simon Fraser University, University of Science and Technology of China, Academia Sinica, Universidad de los Andes, Faculty of Mathematics and Physics, Czech Technical University in Prague, Academy of Sciences, Universidad San Francisco de Quito, University of Helsinki, CNRS/IN2P3, Institut National Polytechnique de Grenoble, Irfu/SPP, RWTH Aachen University, Universität Bonn, Universität Freiburg, Georg-August-Universität Göttingen, Karlsruhe Institute of Technology, Universität Mainz, Ludwig-Maximilians-Universität München, University of Wuppertal, University of Athens, Panjab University, Delhi University, Tata Institute of Fundamental Research, University College Dublin, Istituto Nazionale di Fisica Nucleare Bologna, University of Bologna, Istituto Nazionale di Fisica Nucleare, Sezione di Padova-Trento, University of Padova, Istituto Nazionale di Fisica Nucleare Pisa, University of Pisa, University of Siena, Scuola Normale Superiore, Sezione di Roma 1, Sapienza Università di Roma, Istituto Nazionale di Fisica Nucleare Trieste/Udine, University of Trieste, Okayama University, Osaka City University, University of Tsukuba, Waseda University, Kyungpook National University, Korea University, SungKyunKwan University, CINVESTAV, NIKHEF, Radboud University Nijmegen/NIKHEF, Joint Institute for Nuclear Research, Institution for Theoretical and Experimental Physics, Moscow State University, Institute for High Energy Physics, Petersburg Nuclear Physics Institute, Comenius University, Universitat Autonoma de Barcelona, Medioambientales y Tecnologicas, University of Cantabria, Stockholm University, University of Geneva, Glasgow University, Lancaster University, University of Liverpool, Imperial College London, University College London, The University of Manchester, University of Oxford, University of Arizona, Ernest Orlando Lawrence Berkeley National Laboratory, University of California, Yale University, University of Florida, Florida State University, Argonne National Laboratory, Fermi National Accelerator Laboratory, University of Chicago, University of Illinois at Chicago, Northern Illinois University, Northwestern University, University of Illinois, Indiana University, Purdue University Calumet, University of Notre Dame, Purdue University, Iowa State University, University of Kansas, Kansas State University, Louisiana Tech University, The Johns Hopkins University, University of Maryland, Boston University, Northeastern University, Harvard University, Massachusetts Institute of Technology, Tufts University, Brandeis University, University of Michigan, Wayne State University, Michigan State University, University of Mississippi, University of Nebraska, Rutgers University, Princeton University, University of New Mexico, State University of New York, Columbia University, The Rockefeller University, University of Rochester, Brookhaven National Laboratory, Duke University, The Ohio State University, Langston University, University of Oklahoma, Oklahoma State University, University of Pennsylvania, Carnegie Mellon University, University of Pittsburgh, Brown University, University of Texas, Texas A and M University, Southern Methodist University, Rice University, Baylor University, University of Virginia, University of Washington, University of Wisconsin, Sezione di Cagliari, University of Toronto, TRIUMF, York University, Seoul National University, Sungkyunkwan University, Institute of Science and Technology Information, Chonnam National University, Chonbuk National University, Institute of Experimental Physics, University of Cyprus, University of Edinburgh, Fukui Prefecture, Kinki University, Universidad Iberoamericana, University of Iowa, University of California Irvine, Cornell University, University of London, University of Manchester, Inc., Nagasaki Institute of Applied Science, Obninsk State University, University de Oviedo, Texas Tech University, CSIC-Universitat de Valencia, Universidad Tecnica Federico Santa Maria, Bergische Universität Wuppertal, Yarmouk University, J. Stefan Institute, Augustana College, SLAC, ICREA/IFAE, Centro de Investigacion en Computacion-IPN, Universidad Autonoma de Sinaloa, Universiẗt Bern, University of Massachusetts Amherst, Universiteit Antwerpen, University of Bristol, University of California Santa Cruz, Chinese Academy of Sciences, Clark, Allan Geoffrey, Garcia Navarro, Jose Enrique, Lister, Alison, and Wu, Xin

Subjects
Particle physics, Astrophysics::High Energy Astrophysical Phenomena, Tevatron, FOS: Physical sciences, General Physics and Astronomy, Elementary particle, ddc:500.2, PARTON DISTRIBUTIONS, HADRON COLLIDERS, QCD, NNLO, 7. Clean energy, 01 natural sciences, 114 Physical sciences, High Energy Physics - Experiment, Standard Model, Nuclear physics, High Energy Physics - Experiment (hep-ex), Particle decay, 0103 physical sciences, [PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex], Grand Unified Theory, Fermilab, TEVATRON, Nuclear Experiment, 010306 general physics, Boson, Physics, HIGGS BOSON, 010308 nuclear & particles physics, High Energy Physics::Phenomenology, 3. Good health, Higgs boson, CDF, Physics::Accelerator Physics, High Energy Physics::Experiment, +W%2B+W-+|+W%3A+pair+production+|+W%3A+leptonic+decay+|+dilepton%3A+final+state+|+jet%3A+multiplicity+|+cross+section%3A+upper+limit+|+mass+dependence+|+Higgs+particle%3A+mass+|+background+|+DZERO+|+CDF+|+Batavia+TEVATRON+Coll+|+anti-p+p+-->+Higgs+particle+anything+|+anti-p+p+-->+Higgs+particle+anything+intermediate+boson+anything+|+anti-p+p+-->+Higgs+particle+anything+quark+antiquark+anything+|+1960+GeV-cms%22">Anti-p p: interaction | Higgs particle: search for | gluon gluon: fusion | intermediate boson: fusion | quark antiquark: annihilation | Higgs particle: decay | Higgs particle --> W+ W- | W: pair production | W: leptonic decay | dilepton: final state | jet: multiplicity | cross section: upper limit | mass dependence | Higgs particle: mass | background | DZERO | CDF | Batavia TEVATRON Coll | anti-p p --> Higgs particle anything | anti-p p --> Higgs particle anything intermediate boson anything | anti-p p --> Higgs particle anything quark antiquark anything | 1960 GeV-cms
Abstract

11 páginas, 4 figuras, 1 tabla.-- CDF Collaboration: et al., We combine searches by the CDF and D0 Collaborations for a Higgs boson decaying to W+W-. The data correspond to an integrated total luminosity of 4.8 (CDF) and 5.4 (D0) fb(-1) of p (p) over bar collisions at root s = 1.96 TeV at the Fermilab Tevatron collider. No excess is observed above background expectation, and resulting limits on Higgs boson production exclude a standard model Higgs boson in the mass range 162-166 GeV at the 95% C.L., We thank the Fermilab staff and the technical staffs of the participating institutions for their vital contributions. This work was supported by DOE and NSF (USA), CONICET and UBACyT (Argentina), CNPq, FAPERJ, FAPESP and FUNDUNESP (Brazil), CRC Program, CFI, NSERC and WestGrid Project (Canada), CAS and CNSF (China), Colciencias (Colombia), MSMT and GACR (Czech Republic), Academy of Finland (Finland), CEA and CNRS/IN2P3 (France), BMBF and DFG (Germany), Ministry of Education, Culture, Sports, Science and Technology (Japan), World Class University Program, National Research Foundation (Korea), KRF and KOSEF (Korea), DAE and DST (India), SFI (Ireland),INFN (Italy), CONACyT (Mexico), NSC(Republic of China), FASI, Rosatom and RFBR (Russia), Slovak R&D Agency (Slovakia), Ministerio de Ciencia e Innovación, and Programa Consolider-Ingenio 2010 (Spain), The Swedish Research Council (Sweden), Swiss National Science Foundation (Switzerland), FOM (The Netherlands), STFC and the Royal Society (UK), and the A.P. Sloan Foundation (USA).

Published
2010

32. Epidemiological analysis of confirmed mpox cases, Burundi, 3 July to 9 September 2024.

Author

Nizigiyimana A, Ndikumwenayo F, Houben S, Manirakiza M, van Lettow M, Liesenborghs L, Mbala-Kingebeni P, Rimoin AW, Bogoch II, and Kindrachuk J

Subjects
Humans, Burundi epidemiology, Female, Adolescent, Male, Child, Child, Preschool, Adult, Young Adult, Infant, Middle Aged, Polymerase Chain Reaction, Age Distribution, Sex Distribution, Population Surveillance, Disease Outbreaks, Mpox (monkeypox) epidemiology, Mpox (monkeypox) virology, Mpox (monkeypox) diagnosis
Abstract

We analysed mpox cases in Burundi from July to September 2024, following the introduction of Clade Ib virus. Of 607 samples from the whole population of suspected cases, 154 were PCR-positive, of whom 85 were children under 15 years, with a higher proportion of female children testing positive. Geographical analysis demonstrates case concentration in Bujumbura Mairie (91/154). Age- and sex-specific interventions, as well as community engagement, are important for outbreak containment, as are targeted public health strategies in Burundi.

Published
2024
Full Text
View/download PDF

33. Seroprevalence and placental transfer of SARS-CoV-2 antibodies in unvaccinated pregnant women.

Author

Vercoutere A, Zina MJ, Telis M, Goffard JC, Boulvain M, de Doncker L, Derisbourg S, Houben S, Delforge ML, Daelemans C, and Kelen D

Subjects
Humans, Female, Pregnancy, Seroepidemiologic Studies, Adult, Infant, Newborn, Spike Glycoprotein, Coronavirus immunology, Placenta immunology, Young Adult, Infectious Disease Transmission, Vertical, Maternal-Fetal Exchange immunology, COVID-19 immunology, COVID-19 epidemiology, SARS-CoV-2 immunology, Antibodies, Viral blood, Immunoglobulin G blood, Pregnancy Complications, Infectious epidemiology, Pregnancy Complications, Infectious immunology
Abstract

Purpose: Pregnant women are at risk of severe SARS-CoV-2 infection, potentially leading to obstetric and neonatal complications. Placental transfer of antibodies directed to SARS-CoV-2 may be protective against neonatal COVID-19, but this remains to be studied. We aimed to determine the seroprevalence of SARS-CoV-2 antibodies in a population of unvaccinated pregnant women and to determine the placental transfer of these antibodies., Methodology: A total of 1197 unvaccinated women with mostly unknown pre-study SARS-CoV-2 infection status, were tested at delivery for SARS-CoV-2 spike protein IgG antibodies during the first year of the pandemic. Umbilical cord samples were collected and assessed for seropositivity if the mother was seropositive. Maternal characteristics, pregnancy and neonatal outcomes and data on SARS-CoV-2 infection were extracted from medical records., Results: Specific IgG were detected in 258 women (21.6%). A significant placental transfer to the newborn was observed in 81.3% of cases. The earlier in the 2nd and 3rd trimesters that the mother had contracted the disease and the more symptomatic she was, the greater the likelihood of transplacental transfer of IgG to her newborn., Conclusion: Approximately one in five women had detectable anti-SARS-CoV-2 spike protein IgG antibodies at delivery during the first year of the pandemic, and these antibodies were significantly transferred to their fetuses. This research provides further evidence to better understand the dynamics of the placental transfer of SARS-CoV-2 IgG antibodies from mothers to their newborns, which is necessary to improve vaccination strategies., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

34. Genomic monitoring of SARS-CoV-2 variants using sentinel SARI hospital surveillance.

Author

Denayer S, Dufrasne FE, Monsieurs B, van Eycken R, Houben S, Seyler L, Demuyser T, van Nedervelde E, Bourgeois M, Delaere B, Magerman K, Jouck D, Lissoir B, Sion C, Reynders M, Petit E, Dauby N, Hainaut M, Laenen L, Maes P, Baele G, Dellicour S, Cuypers L, André E, Couvreur S, Brondeel R, Barbezange C, Bossuyt N, and van Gucht S

Subjects
Humans, SARS-CoV-2 genetics, Pandemics, Sentinel Surveillance, Genomics, Hospitals, COVID-19 diagnosis, COVID-19 epidemiology, Pneumonia
Abstract

Background: To support the COVID-19 pandemic response, many countries, including Belgium, implemented baseline genomic surveillance (BGS) programs aiming to early detect and characterize new SARS-CoV-2 variants. In parallel, Belgium maintained a sentinel network of six hospitals that samples patients with severe acute respiratory infections (SARI) and integrated SARS-CoV-2 detection within a broader range of respiratory pathogens. We evaluate the ability of the SARI surveillance to monitor general trends and early signals of viral genetic evolution of SARS-CoV-2 and compare it with the BGS as a reference model., Methods: Nine-hundred twenty-five SARS-CoV-2 positive samples from patients fulfilling the Belgian SARI definition between January 2020 and December 2022 were sequenced using the ARTIC Network amplicon tiling approach on a MinION platform. Weekly variant of concern (VOC) proportions and types were compared to those that were circulating between 2021 and 2022, using 96,251 sequences of the BGS., Results: SARI surveillance allowed timely detection of the Omicron (BA.1, BA.2, BA.4, and BA.5) and Delta (B.1.617.2) VOCs, with no to 2 weeks delay according to the start of their epidemic growth in the Belgian population. First detection of VOCs B.1.351 and P.1 took longer, but these remained minor in Belgium. Omicron BA.3 was never detected in SARI surveillance. Timeliness could not be evaluated for B.1.1.7, being already major at the start of the study period., Conclusions: Genomic surveillance of SARS-CoV-2 using SARI sentinel surveillance has proven to accurately reflect VOCs detected in the population and provides a cost-effective solution for long-term genomic monitoring of circulating respiratory viruses., Competing Interests: The authors declare no conflict of interest., (© 2023 Sciensano and The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

35. Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.

Author

Pannus P, Depickère S, Kemlin D, Georges D, Houben S, Olislagers V, Waegemans A, De Craeye S, Francotte A, Chaumont F, Van Oostveldt C, Heyndrickx L, Michiels J, Willems E, Dhondt E, Krauchuk M, Schmickler MN, Verbrugghe M, Van Loon N, Dierick K, Matagne A, Desombere I, Ariën KK, Marchant A, and Goossens ME

Subjects
Humans, Adult, Population Groups, BNT162 Vaccine, SARS-CoV-2, Breakthrough Infections, Nursing Homes, RNA, Messenger, Immunity, Antibodies, Viral, mRNA Vaccines, COVID-19 Vaccines, COVID-19 prevention & control
Abstract

Background: Nursing home residents, a frail and old population group, respond poorly to primary mRNA COVID-19 vaccination. A third dose has been shown to boost protection against severe disease and death in this immunosenescent population, but limited data is available on the immune responses it induces., Methods: In this observational cohort study, peak humoral and cellular immune responses were compared 28 days after the second and third doses of the BNT162b2 mRNA COVID-19 vaccine in residents and staff members of two Belgian nursing homes. Only individuals without evidence of previous SARS-CoV-2 infection at third dose administration were included in the study. In addition, an extended cohort of residents and staff members was tested for immune responses to a third vaccine dose and was monitored for vaccine breakthrough infections in the following six months. The trial is registered on ClinicalTrials.gov (NCT04527614)., Findings: All included residents (n = 85) and staff members (n = 88) were SARS-CoV-2 infection naïve at third dose administration. Historical blood samples from 28 days post second dose were available from 42 residents and 42 staff members. Magnitude and quality of humoral and cellular immune responses were strongly boosted in residents post third compared to post second dose. Increases were less pronounced in staff members than in residents. At 28 days post third dose, differences between residents and staff had become mostly insignificant. Humoral, but not cellular, responses induced by a third dose were predictive of subsequent incidence of vaccine breakthrough infection in the six months following vaccination., Interpretation: These data show that a third dose of mRNA COVID-19 vaccine largely closes the gap in humoral and cellular immune response observed after primary vaccination between NH residents and staff members but suggest that further boosting might be needed to achieve optimal protection against variants of concern in this vulnerable population group., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023. Published by Elsevier Ltd.)

Published
2023
Full Text
View/download PDF

36. Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial.

Author

Pannus P, Depickère S, Kemlin D, Houben S, Neven KY, Heyndrickx L, Michiels J, Willems E, De Craeye S, Francotte A, Chaumont F, Olislagers V, Waegemans A, Verbrugghe M, Schmickler MN, Van Gucht S, Dierick K, Marchant A, Desombere I, Ariën KK, and Goossens ME

Abstract

Fractional dosing of COVID-19 vaccines could accelerate vaccination rates in low-income countries. Dose-finding studies of the mRNA vaccine BNT162b2 (Pfizer-BioNTech) suggest that a fractional dose induces comparable antibody responses to the full dose in people <55 years. Here, we report the safety and immunogenicity of a fractional dose regimen of the BNT162b2 vaccine. REDU-VAC is a participant-blinded, randomised, phase 4, non-inferiority study. Adults 18-55 years old, either previously infected or infection naïve, were randomly assigned to receive 20μg/20μg (fractional dose) or 30μg/30μg (full dose) of BNT162b2. The primary endpoint was the geometric mean ratio (GMR) of SARS-CoV-2 anti-RBD IgG titres at 28 days post second dose between the reduced and full dose regimens. The reduced dose was considered non-inferior to the full dose if the lower limit of the two-sided 95% CI of the GMR was >0.67. Primary analysis was done on the per-protocol population, including infection naïve participants only. 145 participants were enrolled and randomized, were mostly female (69.5%), of European origin (95%), with a mean age of 40.4 years (SD 7.9). At 28 days post second dose, the geometric mean titre (GMT) of anti-RBD IgG of the reduced dose regimen (1,705 BAU/mL) was not non-inferior to the full dose regimen (2,387 BAU/mL), with a GMR of 0.714 (two-sided 95% CI 0.540-0.944). No serious adverse events occurred. While non-inferiority of the reduced dose regimen was not demonstrated, the anti-RBD IgG titre was only moderately lower than that of the full dose regimen and, importantly, still markedly higher than the reported antibody response to the licensed adenoviral vector vaccines. These data suggest that reduced doses of the BNT162b2 mRNA vaccine may offer additional benefit as compared to the vaccines currently in use in most low and middle-income countries, warranting larger immunogenicity and effectiveness trials. Trial Registration: The trial is registered at ClinicalTrials.gov (NCT04852861)., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2022 Pannus et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Published
2022
Full Text
View/download PDF

37. The Impact of COVID-19 Infection on Cognitive Function and the Implication for Rehabilitation: A Systematic Review and Meta-Analysis.

Author

Houben S and Bonnechère B

Subjects
Cognition, Humans, COVID-19
Abstract

There is mounting evidence that patients with severe COVID-19 disease may have symptoms that continue beyond the acute phase, extending into the early chronic phase. This prolonged COVID-19 pathology is often referred to as 'Long COVID'. Simultaneously, case investigations have shown that COVID-19 individuals might have a variety of neurological problems. The accurate and accessible assessment of cognitive function in patients post-COVID-19 infection is thus of increasingly high importance for both public and individual health. Little is known about the influence of COVID-19 on the general cognitive levels but more importantly, at sub-functions level. Therefore, we first aim to summarize the current level of evidence supporting the negative impact of COVID-19 infection on cognitive functions. Twenty-seven studies were included in the systematic review representing a total of 94,103 participants (90,317 COVID-19 patients and 3786 healthy controls). We then performed a meta-analysis summarizing the results of five studies (959 participants, 513 patients) to quantify the impact of COVID-19 on cognitive functions. The overall effect, expressed in standardized mean differences, is -0.41 [95%CI -0.55; -0.27]. To prevent disability, we finally discuss the different approaches available in rehabilitation to help these patients and avoid long-term complications.

Published
2022
Full Text
View/download PDF

38. What's the Situation with Situated Visualization? A Survey and Perspectives on Situatedness.

Author

Bressa N, Korsgaard H, Tabard A, Houben S, and Vermeulen J

Subjects
Humans, Surveys and Questionnaires, Augmented Reality, Computer Graphics
Abstract

Situated visualization is an emerging concept within visualization, in which data is visualized in situ, where it is relevant to people. The concept has gained interest from multiple research communities, including visualization, human-computer interaction (HCI) and augmented reality. This has led to a range of explorations and applications of the concept, however, this early work has focused on the operational aspect of situatedness leading to inconsistent adoption of the concept and terminology. First, we contribute a literature survey in which we analyze 44 papers that explicitly use the term "situated visualization" to provide an overview of the research area, how it defines situated visualization, common application areas and technology used, as well as type of data and type of visualizations. Our survey shows that research on situated visualization has focused on technology-centric approaches that foreground a spatial understanding of situatedness. Secondly, we contribute five perspectives on situatedness (space, time, place, activity, and community) that together expand on the prevalent notion of situatedness in the corpus. We draw from six case studies and prior theoretical developments in HCI. Each perspective develops a generative way of looking at and working with situatedness in design and research. We outline future directions, including considering technology, material and aesthetics, leveraging the perspectives for design, and methods for stronger engagement with target audiences. We conclude with opportunities to consolidate situated visualization research.

Published
2022
Full Text
View/download PDF

39. Trends in Double Networks as Bioprintable and Injectable Hydrogel Scaffolds for Tissue Regeneration.

Author

Aldana AA, Houben S, Moroni L, Baker MB, and Pitet LM

Subjects
Injections, Regenerative Medicine, Hydrogels, Tissue Engineering
Abstract

Additive manufacturing and injection are essential tools in the rapidly developing field of personalized medicine and are particularly promising for applications in regenerative medicine. One of the biggest challenges in this vibrant research domain remains the processing of complex formulations with robust mechanical properties. Mimicking the native extracellular matrix associated with many tissues requires materials that have high degrees of functionality for performing the complex array of functions within the cellular environment. Furthermore, native tissues often possess outstanding mechanical properties, particularly in connective tissues. These exceptional mechanics are a challenge to emulate in their own right, especially considering the accompanying demands for additional functionality. Double-network hydrogels have emerged as strong candidates for tissue engineering because of the impressive mechanics and versatility in terms of chemical makeup. Combining advances in processing (i.e., additive manufacturing and injection) with dual-network hydrogel formulations has led to an impressive collection of results, making great strides toward systems capable of addressing the demanding environment surrounding tissues while being amenable to personalized fabrication techniques. This review provides a brief summary of the most contemporary trends collected from the literature describing dual-network hydrogels being demonstrated in additive manufacturing and injectable applications.

Published
2021
Full Text
View/download PDF

41. Tau Pathology and Adult Hippocampal Neurogenesis: What Tau Mouse Models Tell us?

Author

Houben S, Homa M, Yilmaz Z, Leroy K, Brion JP, and Ando K

Abstract

Adult hippocampal neurogenesis (AHN) has been widely confirmed in mammalian brains. A growing body of evidence points to the fact that AHN sustains hippocampal-dependent functions such as learning and memory. Impaired AHN has been reported in post-mortem human brain hippocampus of Alzheimer's disease (AD) and is considered to contribute to defects in learning and memory. Neurofibrillary tangles (NFTs) and amyloid plaques are the two key neuropathological hallmarks of AD. NFTs are composed of abnormal tau proteins accumulating in many brain areas during the progression of the disease, including in the hippocampus. The physiological role of tau and impact of tau pathology on AHN is still poorly understood. Modifications in AHN have also been reported in some tau transgenic and tau-deleted mouse models. We present here a brief review of advances in the relationship between development of tau pathology and AHN in AD and what insights have been gained from studies in tau mouse models., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Houben, Homa, Yilmaz, Leroy, Brion and Ando.)

Published
2021
Full Text
View/download PDF

43. Intravenous Injection of PHF-Tau Proteins From Alzheimer Brain Exacerbates Neuroinflammation, Amyloid Beta, and Tau Pathologies in 5XFAD Transgenic Mice.

Author

Houben S, de Fisenne MA, Ando K, Vanden Dries V, Poncelet L, Yilmaz Z, Mansour S, De Decker R, Brion JP, and Leroy K

Abstract

Alzheimer's disease (AD) is characterized by the accumulation in the brain of intraneuronal aggregates of abnormally and hyperphosphorylated tau proteins and of extracellular deposits of amyloid-β surrounded by dystrophic neurites. Numerous experimental models have shown that tau pathology develops in the brain after intracerebral injection of brain homogenates or pathological tau [paired helical filaments (PHF)-tau)] from AD brains. Further investigations are however necessary to identify or exclude potential extracerebral routes of tau pathology transmission, e.g., through the intravascular route. In this study, we have analyzed the effect of intravenous injection of PHF-tau proteins from AD brains on the formation of tau and amyloid pathologies in the brain of wild-type (WT) mice and of 5XFAD mice (an amyloid model). We observed that 5XFAD mice with a disrupted blood-brain barrier showed increased plaque-associated astrogliosis, microgliosis, and increased deposits of Aβ40 and Aβ42 after intravenous injection of PHF-tau proteins. In addition, an increased phosphotau immunoreactivity was observed in plaque-associated dystrophic neurites. These results suggest that blood products contaminated by PHF-tau proteins could potentially induce an exacerbation of neuroinflammation and AD pathologies., (Copyright © 2020 Houben, de Fisenne, Ando, Vanden Dries, Poncelet, Yilmaz, Mansour, De Decker, Brion and Leroy.)

Published
2020
Full Text
View/download PDF

44. Picalm reduction exacerbates tau pathology in a murine tauopathy model.

Author

Ando K, De Decker R, Vergara C, Yilmaz Z, Mansour S, Suain V, Sleegers K, de Fisenne MA, Houben S, Potier MC, Duyckaerts C, Watanabe T, Buée L, Leroy K, and Brion JP

Subjects
Animals, Brain pathology, Disease Models, Animal, Female, Frontotemporal Dementia metabolism, Haploinsufficiency, Humans, Male, Mice, Mice, Transgenic, Middle Aged, Monomeric Clathrin Assembly Proteins metabolism, Tauopathies metabolism, tau Proteins genetics, Monomeric Clathrin Assembly Proteins genetics, Tauopathies genetics, Tauopathies pathology
Abstract

Genome-wide association studies (GWAS) have identified PICALM as one of the most significant susceptibility loci for late-onset Alzheimer's disease (AD) after APOE and BIN1. PICALM is a clathrin-adaptor protein and plays critical roles in clathrin-mediated endocytosis and in autophagy. PICALM modulates brain amyloid ß (Aß) pathology and tau accumulation. We have previously reported that soluble PICALM protein level is reduced in correlation with abnormalities of autophagy markers in the affected brain areas of neurodegenerative diseases including AD, sporadic tauopathies and familial cases of frontotemporal lobar degeneration with tau-immunoreactive inclusions (FTLD-tau) with mutations in the microtubule-associated protein tau (MAPT) gene. It remains unclarified whether in vivo PICALM reduction could either trigger or influence tau pathology progression in the brain. In this study, we confirmed a significant reduction of soluble PICALM protein and autophagy deficits in the post-mortem human brains of FTLD-tau-MAPT (P301L, S364S and L266V). We generated a novel transgenic mouse line named Tg30xPicalm+/- by crossing Tg30 tau transgenic mice with Picalm-haploinsufficient mice to test whether Picalm reduction may modulate tau pathology. While Picalm haploinsufficiency did not lead to any motor phenotype or detectable tau pathology in mouse brains, Tg30xPicalm+/-  mice developed markedly more severe motor deficits than Tg30 by the age of 9 months. Tg30xPicalm+/-  had significantly higher pathological tau levels in the brain, an increased density of neurofibrillary tangles compared to Tg30 mice and increased abnormalities of autophagy markers. Our results demonstrate that Picalm haploinsufficiency in transgenic Tg30 mice significantly aggravated tau pathologies and tau-mediated neurodegeneration, supporting a role for changes in Picalm expression as a risk/sensitizing factor for development of tau pathology and as a mechanism underlying the AD risk associated to PICALM.

Published
2020
Full Text
View/download PDF

45. Genetic ablation of tau in postnatal neurons rescues decreased adult hippocampal neurogenesis in a tauopathy model.

Author

Houben S, Leroy K, Ando K, Yilmaz Z, Widomski C, Buée L, and Brion JP

Subjects
Animals, Cell Proliferation physiology, Doublecortin Protein, Hippocampus pathology, Memory physiology, Mice, Mice, Transgenic, Neural Stem Cells metabolism, Neurons pathology, Tauopathies genetics, Tauopathies pathology, tau Proteins genetics, Hippocampus metabolism, Neurogenesis genetics, Neurons metabolism, Tauopathies metabolism, tau Proteins metabolism
Abstract

Impaired adult hippocampal neurogenesis has been reported as a feature of Alzheimer's disease and other tauopathies and might contribute to defects in learning and memory in these diseases. To assess the interference of tau pathology, a common key-lesion in these diseases, with adult hippocampal neurogenesis we analyzed adult neurogenesis in the hippocampal dentate gyrus in wild-type mice, Tg30 mice expressing a FTDP-17 mutant tau and the same Tg30 mice deficient for mouse tau (Tg30/tauKO). The volume of the granular layer, the number of granule cells and of neuronal precursors expressing the immature markers DCX or 3R-tau were analyzed in the dentate gyrus (DG) using unbiased stereological methods. The co-localization of neurogenic markers with the human mutant tau was also analyzed. We observed a significant reduction of the volume of the granular layer and of granule cells number in mutant tau Tg30 mice, but not in Tg30/tauKO mice. The number of neuronal precursors expressing the immature markers DCX or 3R-tau (the latter only expressed in wild-type and Tg30 mice) and the number of cells expressing the proliferation marker Ki-67 in the neurogenic subgranular zone of the DG was reduced in Tg30 but not in Tg30/tauKO mice. The density of phosphotau positive cells in the DG and the level of soluble human phosphotau was lower in Tg30/tauKO compared to Tg30 mice. The human mutant tau was expressed in mature granule cells in Tg30 and Tg30/tauKO mice but was not expressed in Sox2 positive neural stem cells and in DCX positive neuronal precursors/immature newborn neurons. These results demonstrate an impairment of adult hippocampal neurogenesis in a FTDP-17 mutant tau mice resulting from a decrease of proliferation affecting the pool of neuronal precursors. The mutant tau was not expressed in precursors cells in these mutant tau mice, suggesting that this neurogenic defect is cell non-autonomous. Interestingly, expression of endogenous wild-type tau in mature granule cells was necessary to observe this toxic effect of human mutant tau, since this impaired adult neurogenesis was rescued by lowering tau expression in Tg30/tauKO mice. These observations suggest that development of tau pathology in granule cells of the dentate gyrus is responsible for reduction of adult hippocampal neurogenesis also in human tauopathies by impairing proliferation of neuronal precursors, and that reduction of tau expression might be an approach to rescue this impairment., (Copyright © 2019 Elsevier Inc. All rights reserved.)

Published
2019
Full Text
View/download PDF

46. Amyloid-β pathology enhances pathological fibrillary tau seeding induced by Alzheimer PHF in vivo.

Author

Vergara C, Houben S, Suain V, Yilmaz Z, De Decker R, Vanden Dries V, Boom A, Mansour S, Leroy K, Ando K, and Brion JP

Subjects
Animals, Humans, Mice, Mice, Knockout, Alzheimer Disease pathology, Amyloid beta-Peptides metabolism, Neurofibrillary Tangles pathology, tau Proteins metabolism
Abstract

Neuropathological analysis in Alzheimer's disease (AD) and experimental evidence in transgenic models overexpressing frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17) mutant tau suggest that amyloid-β pathology enhances the development of tau pathology. In this work, we analyzed this interaction independently of the overexpression of an FTDP-17 mutant tau, by analyzing tau pathology in wild-type (WT), 5xFAD, APP -/- and tau -/- mice after stereotaxic injection in the somatosensory cortex of short-length native human AD-PHF. Gallyas and phosphotau-positive tau inclusions developed in WT, 5xFAD, and APP -/- but not in tau -/- mice. Ultrastructural analysis demonstrated their intracellular localization and that they were composed of straight filaments. These seeded tau inclusions were composed only of endogenous murine tau exhibiting a tau antigenic profile similar to tau aggregates in AD. Insoluble tau level was higher and ipsilateral anteroposterior and contralateral cortical spreading of tau inclusions was more important in AD-PHF-injected 5xFAD mice than in WT mice. The formation of large plaque-associated dystrophic neurites positive for oligomeric and phosphotau was observed in 5xFAD mice injected with AD-PHF but never in control-injected or in non-injected 5xFAD mice. An increased level of the p25 activator of CDK5 kinase was found in AD-PHF-injected 5xFAD mice. These data demonstrate in vivo that the presence of Aβ pathology enhances experimentally induced tau seeding of endogenous, wild-type tau expressed at physiological level, and demonstrate the fibrillar nature of heterotopically seeded endogenous tau. These observations further support the hypothesis that Aβ enhances tau pathology development in AD through increased pathological tau spreading.

Published
2019
Full Text
View/download PDF

47. Effects of press-fit biphasic (collagen and HA/βTCP) scaffold with cell-based therapy on cartilage and subchondral bone repair knee defect in rabbits.

Author

Hernigou J, Vertongen P, Chahidi E, Kyriakidis T, Dehoux JP, Crutzen M, Boutry S, Larbanoix L, Houben S, Gaspard N, Koulalis D, and Rasschaert J

Subjects
Animals, Bone Regeneration physiology, Cartilage, Articular metabolism, Cartilage, Articular physiopathology, Collagen Type I pharmacology, Collagen Type II metabolism, Durapatite pharmacology, Female, Immunohistochemistry, Knee Joint metabolism, Knee Joint surgery, Magnetic Resonance Imaging, Rabbits, Cartilage, Articular surgery, Knee Joint physiopathology, Mesenchymal Stem Cell Transplantation methods, Tissue Scaffolds
Abstract

Introduction: Human spontaneous osteonecrosis of the knee (SPONK) is still challenging as the current treatments do not allow the production of hyaline cartilage tissue. The aim of the present study was to explore the therapeutic potential of cartilage regeneration using a new biphasic scaffold (type I collagen/hydroxyapatite) previously loaded or not with concentrated bone marrow cells., Material and Methods: Female rabbits were operated of one knee to create articular lesions of the trochlea (three holes of 4 × 4mm). The holes were left empty in the control group or were filled with the scaffold alone or the scaffold previously loaded with concentrated bone marrow cells. After two months, rabbits were sacrificed and the structure of the newly formed tissues were evaluated by macroscopic, MRI, and immunohistochemistry analyses., Results: Macroscopic and MRI evaluation of the knees did not show differences between the three groups (p > 0.05). However, histological analysis demonstrated that a higher O'Driscoll score was obtained in the two groups treated with the scaffold, as compared to the control group (p < 0.05). The number of cells in treated area was higher in scaffold groups compared to the control group (p < 0.05). There was no difference for intensity of collagen type II between the groups (p > 0.05) but subchondral bone repair was significantly thicker in scaffold-treated groups than in the control group (1 mm for the control group vs 2.1 and 2.6 mm for scaffold groups). Furthermore, we observed that scaffolds previously loaded with concentrated bone marrow were more reabsorbed (p < 0.05)., Conclusion: The use of a biphasic scaffold previously loaded with concentrated bone marrow significantly improves cartilage lesion healing.

Published
2018
Full Text
View/download PDF

48. Cold tolerance of third-instar Drosophila suzukii larvae.

Author

Jakobs R, Ahmadi B, Houben S, Gariepy TD, and Sinclair BJ

Subjects
Animals, Drosophila growth & development, Female, Larva growth & development, Larva physiology, Male, Acclimatization, Cold Temperature adverse effects, Drosophila physiology
Abstract

Drosophila suzukii is an emerging global pest of soft fruit; although it likely overwinters as an adult, larval cold tolerance is important both for determining performance during spring and autumn, and for the development of temperature-based control methods aimed at larvae. We examined the low temperature biology of third instar feeding and wandering larvae in and out of food. We induced phenotypic plasticity of thermal biology by rearing under short days and fluctuating temperatures (5.5-19°C). Rearing under fluctuating temperatures led to much slower development (42.1days egg-adult) compared to control conditions (constant 21.5°C; 15.7days), and yielded larger adults of both sexes. D. suzukii larvae were chill-susceptible, being killed by low temperatures not associated with freezing, and freezing survival was not improved when ice formation was inoculated externally via food or silver iodide. Feeding larvae were more cold tolerant than wandering larvae, especially after rearing under fluctuating temperatures, and rearing under fluctuating temperatures improved survival of prolonged cold (0°C) to beyond 72h in both larval stages. There was no evidence that acute cold tolerance could be improved by rapid cold-hardening. We conclude that D. suzukii has the capacity to develop at low temperatures under fluctuating temperatures, but that they have limited cold tolerance. However, phenotypic plasticity of prolonged cold tolerance must be taken into account when developing low temperature treatments for sanitation of this species., (Crown Copyright © 2016. Published by Elsevier Ltd. All rights reserved.)

Published
2017
Full Text
View/download PDF

49. High-Molecular-Weight Paired Helical Filaments from Alzheimer Brain Induces Seeding of Wild-Type Mouse Tau into an Argyrophilic 4R Tau Pathology in Vivo.

Author

Audouard E, Houben S, Masaracchia C, Yilmaz Z, Suain V, Authelet M, De Decker R, Buée L, Boom A, Leroy K, Ando K, and Brion JP

Subjects
Aged, Aged, 80 and over, Alzheimer Disease metabolism, Animals, Behavior, Animal, Brain metabolism, Brain pathology, CHO Cells, Cricetulus, Cytoskeleton metabolism, Disease Models, Animal, Female, Hippocampus metabolism, Hippocampus pathology, Humans, Male, Mice, Mice, Inbred C57BL, Neurofibrillary Tangles metabolism, Protein Isoforms, tau Proteins genetics, Alzheimer Disease pathology, Cytoskeleton pathology, Neurofibrillary Tangles pathology, tau Proteins metabolism
Abstract

In Alzheimer disease, the development of tau pathology follows neuroanatomically connected pathways, suggesting that abnormal tau species might recruit normal tau by passage from cell to cell. Herein, we analyzed the effect of stereotaxic brain injection of human Alzheimer high-molecular-weight paired helical filaments (PHFs) in the dentate gyrus of wild-type and mutant tau THY-Tau22 mice. After 3 months of incubation, wild-type and THY-Tau22 mice developed an atrophy of the dentate gyrus and a tau pathology characterized by Gallyas and tau-positive grain-like inclusions into granule cells that extended in the hippocampal hilus and eventually away into the alveus, and the fimbria. Gallyas-positive neuropil threads and oligodendroglial coiled bodies were also observed. These tau inclusions were composed only of mouse tau, and were immunoreactive with antibodies to 4R tau, phosphotau, misfolded tau, ubiquitin, and p62. Although local hyperphosphorylation of tau was increased in the dentate gyrus in THY-Tau22 mice, the development of neurofibrillary tangles made of mutant human tau was not accelerated in the hippocampus, indicating that wild-type human PHFs were inefficient in seeding tau aggregates made of G272V/P301S mutant human tau. Our results indicate thus that injection of human wild-type Alzheimer PHF seeded aggregation of wild-type murine tau into an argyrophilic 4R tau pathology, and constitutes an interesting model independent of expression of a mutant tau protein., (Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.)

Published
2016
Full Text
View/download PDF

50. Folliculogenesis Is Not Fully Inhibited during GnRH Analogues Treatment in Mice Challenging Their Efficiency to Preserve the Ovarian Reserve during Chemotherapy in This Model.

Author

Horicks F, Van Den Steen G, Houben S, Englert Y, and Demeestere I

Subjects
Animals, Dose-Response Relationship, Drug, Female, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Models, Animal, Ovarian Follicle cytology, Antineoplastic Agents adverse effects, Cyclophosphamide adverse effects, Gonadotropin-Releasing Hormone analogs & derivatives, Gonadotropin-Releasing Hormone pharmacology, Ovarian Follicle drug effects, Ovarian Reserve drug effects
Abstract

As many chemotherapy regimens induce follicular depletion, fertility preservation became a major concern in young cancer patients. By maintaining follicles at the resting stage, gonadotropin-releasing hormone analogues (GnRHa) were proposed as an ovarian-protective option during chemotherapy. However, their efficacy and mechanisms of action remain to be elucidated. Mice were dosed with cyclophosphamide (Cy, 100-500 mg/kg i.p) to quantify follicular depletion and evaluate apoptosis at different times. We observed a dose-dependent depletion of the follicular reserve within 24 hours after Cy injection with a mean follicular loss of 45% at the dose of 200mg/kg. Apoptosis occurs in the granulosa cells of growing follicles within 12 hours after Cy treatment, while no apoptosis was detected in resting follicles suggesting that chemotherapy acutely affects both resting and growing follicles through different mechanisms. We further tested the ability of both GnRH agonist and antagonist to inhibit oestrus cycles, follicular growth and FSH secretion in mice and to protect ovarian reserve against chemotherapy. Although GnRHa were efficient to disrupt oestrus cycles, they failed to inhibit follicular development, irrespective of the doses and injection sites (sc or im). Around 20% of healthy growing follicles were still observed during GnRHa treatment and serum FSH levels were not reduced either by antagonist or agonist. GnRHa had no effect on Cy-induced follicular damages. Thus, we showed that GnRHa were not as efficient at inhibiting the pituitary-gonadal axis in mice as in human. Furthermore, the acute depletion of primordial follicles observed after chemotherapy does not support the hypothesis that the ovary may be protected by gonadotropin suppression.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results